PEPTIDE CORTEXThe library
← The library

Elamipretide

Forzinity/SS-31Longevity
Evidence grade
AFDA-approved Rx (labeled use)
Cardiovascular · 0–5 · separate axis
2
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeLongevity / Mitochondrial
MechanismMitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, improving cristae structure and respiration
EffectsRestores mitochondrial membrane structure; the first mitochondria-targeted peptide to reach FDA approval (2025)
Dosing40 mg SC once daily (per labelled indication)
Bottom lineStrongest data when used for its labeled indication under clinician guidance.
Protocols · as published3 sourced
FDA labelForzinity (Barth syndrome, accelerated approval 2025-09-19)
RouteSubcutaneous
FrequencyOnce daily, same time each day
Starting40 mg SC once daily (patients at least 30 kg)
EscalationNone
Target40 mg SC once daily

Severe renal impairment (eGFR <30, not on dialysis): reduce to 20 mg once daily. Skip a missed dose; do not double.

Clinical trialTAZPOWER, Barth syndrome (phase 2/3)
RouteSubcutaneous
FrequencyOnce daily
Starting40 mg SC daily
EscalationNone
Target40 mg SC daily, 12-week randomised crossover periods, then open-label extension
Community protocol — not clinically establishedCommunity guide (as SS-31)
RouteSubcutaneous
FrequencyOnce daily
Starting"Micro-start" 0.1-1 mg daily
EscalationCommon cluster 1-5 mg daily; "guide-page standard" 5-10 mg; "performance-oriented" 10-20 mg daily
TargetVaries 1-20 mg/day
Cycle1-5 mg cluster run for 4-8 weeks

"Published human SS-31 evidence does not establish an anti-aging, athletic-performance, or healthy-adult dose."

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Injection-site reactions; approved only for Barth syndrome — longevity use is off-label and unstudied

Limited published interaction data; follow the prescribing information and clinician guidance.

CV 2 of 5 — Cardiolipin is concentrated in cardiac tissue and heart-failure trials were run, but the approved indication is Barth syndrome, not cardiac disease.